Pioglitazone Attenuates Dysmetabolism in Peritoneal Dialysis (PD) Patients
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
1. Background:Cardiovascular disease (CVD) is the major cause of mortality in peritoneal
dialysis (PD) patients, in whom it is partly attributable to a higher prevalence of
dysmetabolism. Currently, few treatments are available with a proven effect on
dyslipidemia, insulin resistance and inflammation in this patient group.
2. Study design: Randomized, cross-over trial.
3. Settings and Participants: Prevalent PD patients (>20 years old, s-triglycerides >1.8
mmol/L) who had never received glitazones were enrolled.
4. Interventions: Participants were randomized to receive either oral pioglitazone (PIO; 15
mg once daily) and no pioglitazone, both for 12 weeks and in random order, with a
four-week wash out in between.
5. Outcomes and measurements: The primary endpoint was change of serum triglyceride (TG)
level during the PIO as compared to no PIO. Secondary endpoints included changes in
other lipid levels, HOMA-IR, adipocytokines and CRP. Outcome effects were assessed using
a GLM.